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Management of Alveolar Proteinosis by Bronchopulmonary 
Lavage under Extra Corporeal Membrane Oxygenation (ECMO) 
 
 




The gold standard of treating Pulmonary Alveolar Proteinosis (PAP) is 
bronchopulmonary lavage (BPL). We describe a rare case of BPD for PAP, 
who underwent extracorporeal membrane oxygenation (ECMO) due to 
hypoventilation in the setting of one-lung ventilation. First, the clinical course 
of the patient is presented; furthermore, the biomolecular basis of PAP and 
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Pulmonary Alveolar Proteinosis (PAP) is a rare and 
complex disease due to the abnormal production of 
surfactant. Its annual incidence is around 0.36 per 
million population (1). PAP is more common in male 
smokers between 30 and 59 years old (2). Based on 
the pathological aspect we can divide it into three 
main groups: 1) Congenital PAP, 2) Acquired PAP, 3) 
Secondary PAP (1). 
The most common type is the acquired type 
which has an auto-immune basis and accounted for 
90% of cases (3). Surfactant homeostasis and 
molecular basis of PAP can be described in figure 1 
(4). 
The gold standard for the treatment of PAP is 
Whole Lung Lavage (WLL) (5). 60% of patients will 
fully recover after two WLL, 5% will require WLL 
every 6 months, and less than 10% will be 
unresponsive to our treatment (3). And the cause of 
death in this disease would be uncontrolled infection 
(72%), Respiratory Failure secondary to PAP (20%), 




A 28-year-old man with a history of cigarette and 
opium smoking was referred due to severe dyspnea 
and chest pain. At first, he was treated with a 
diagnosis of pneumonia but had not fully recovered. 
ECMO for Alveolar Proteinosis                                                                                                           Parsa et al. 
Vol 1, No 1, Jan 2016 
41 
On physical examination, his vital signs were as 
follows; Temperature 36°C; Respiratory Rate 25/min; 
Pulse Rate 110/min; Blood Pressure 95/69 mmHg; O2 
Saturation 75% in room air and 92% with facial mask 
6 lit/min. On lung auscultation fine crackle was heard 
at the bases of both lungs. In laboratory examination 
complete blood count and biochemical profile were 
within normal range and ABG was as follows; pH 
7.36; pCO2 60; HCO3 36; pO2 40. 
Further investigation revealed “Crazy Paving 
Pattern” in CT-scan. Therefore he went on 
bronchoscopy for bronchoalveolar lavage (BAL) and 
transbronchial lung biopsy (TBLB). After the 
procedure he was complicated with pneumothorax 
and became intubated and due to desaturation, he 
transferred to ICU. Due to low saturations under 
mechanical ventilation (63-85%) the process of 
weaning had failed and after 5 days Percutaneous 
Dilational Tracheostomy (PDT) was done. At this 
time the pathologic feature of TBLB was consistent 
with PAP therefore he was scheduled for WLL. 
O2 saturation at the arrival to Operating Room 
was 71% with FiO2 100%. After the induction of 
anesthesia, a double lumen #39 was placed and 
checked with fiber optic bronchoscopy. An invasive 
Blood Pressure catheter and central vein catheter were 
placed and cerebral oximetry was done. After one-
lung ventilation and starting of lavage on serial ABG, 
we had respiratory acidosis with pCO2 of 105 and 
pO2 of 53. Due to the rising of pCO2, we decided to 
perform a V-V ECMO. 
For this, a return cannula was placed 
percutaneously in the right internal jugular vein and a 
drainage cannula was inserted in the right femoral 
vein. A 17 Fr. Bio-Medicus (Medtronic, Inc., 
Minneapolis, MN, USA) arterial cannulae was used 
as the return cannula, and a 19 Fr. multi-port Bio-
Medicus (Medtronic, Inc. Minneapolis, MN, USA) 
cannulae for the drainage cannula. ECMO circuits 
consisted of a QuadroxD (Maquet Cardiovascular, 
Wayne, NJ, USA) polymethyl pentene oxygenator 
and a Rotaflow (Maquet Cardiovascular) centrifugal 
pump. Blood flow of 3-5 liter/min was utilized during 
the procedure. After ECMO initiation the blood gas 
values were within the normal range. WLL continued 
with 17 lit of warm Normal Saline for the right lung 
and 13 lit for the left lung under ECMO without any 
complication (Figure 2). The patient was weaned 
from ECMO at the end of the procedure and returned 
to the ICU. 
He was transferred to ICU and after 29 hours 
he was weaned from ECMO with normal ABG 
afterward. Unfortunately 20 days after WLL he was 
expired from resistant pneumonitis. 
 
 




Fig. 2.  Retrieved fluid from right (a) and left (b) lung. 
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Discussion 
Dr. Benjamin Casteleman published the first report on 
PAP in 1953 and Dr. Jose Ramirez-Rivera performed 
the first WLL (1). Since then the histopatho- 
physiologic changes occurring in PAP were well 
studied. In the 1990s GM-CSF models of PAP had 
been published (6). As gene-knocked out mice died 
from a disease with characteristics of PAP, this link 
had been studied. Another consistent finding was 
extracting GM-CSF autoantibodies in the serum of 
patients (7). Consequently, new treatments including 
inhalational and subcutaneous GM-CSF, Rituximab, 
and Plasmapheresis have been advised in various 
reports (1, 5, 6). On the other hand, another therapy 
has been emerged with promising results, in which 
macrophage transplantation is studied for the 
treatment of PAP (8) (Figure 3). 
GM-CSF is a 23 kDa cytokine which produces 
by numeral cells and binds to heterogeneous cell 
receptors (4). Ligation of these proteins forms a 
dodecahedral complex containing α, β, and β-
associated Janus kinase 2 chains. 
Autophosphorylation of Janus kinases produces 
multiple signaling pathways. One of the major effects 
is in the transducer and activator of transcription-5 
(STAT5) with effects on myeloid cells (4). 
Conclusion 
In this case report, several factors led to mortality. 
First, prior history of pneumonitis added to alveolar 
proteinosis made respiratory failure results in 
prolonged intubation and mechanical ventilation. 
Second, based on our experiments the bloody 
retrieved fluid is related to mortality and could be a 
sign of poor prognosis. Third, a new multi-drug 
resistant pneumonitis could cause patterns of ARDS 
and respiratory failure consequently. 
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Fig. 3.  Macrophage Transplantation for resolution 
of PAP. 
